We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Organon (OGN) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
The most recent trading session ended with Organon (OGN - Free Report) standing at $17.45, reflecting a -0.91% shift from the previouse trading day's closing. This change lagged the S&P 500's daily loss of 0.18%. On the other hand, the Dow registered a loss of 0.8%, and the technology-centric Nasdaq increased by 0.27%.
Heading into today, shares of the pharmaceutical company had lost 9.65% over the past month, lagging the Medical sector's loss of 3.03% and the S&P 500's gain of 4.46% in that time.
The investment community will be closely monitoring the performance of Organon in its forthcoming earnings report. The company is scheduled to release its earnings on October 31, 2024. The company's upcoming EPS is projected at $0.91, signifying a 4.6% increase compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $1.56 billion, showing a 2.74% escalation compared to the year-ago quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $4.29 per share and a revenue of $6.35 billion, indicating changes of +3.62% and +1.32%, respectively, from the former year.
Investors might also notice recent changes to analyst estimates for Organon. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.48% lower. Organon currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Organon is currently trading at a Forward P/E ratio of 4.11. This signifies a discount in comparison to the average Forward P/E of 20.32 for its industry.
Meanwhile, OGN's PEG ratio is currently 0.75. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical Services industry currently had an average PEG ratio of 1.85 as of yesterday's close.
The Medical Services industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 173, finds itself in the bottom 32% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Organon (OGN) Dips More Than Broader Market: What You Should Know
The most recent trading session ended with Organon (OGN - Free Report) standing at $17.45, reflecting a -0.91% shift from the previouse trading day's closing. This change lagged the S&P 500's daily loss of 0.18%. On the other hand, the Dow registered a loss of 0.8%, and the technology-centric Nasdaq increased by 0.27%.
Heading into today, shares of the pharmaceutical company had lost 9.65% over the past month, lagging the Medical sector's loss of 3.03% and the S&P 500's gain of 4.46% in that time.
The investment community will be closely monitoring the performance of Organon in its forthcoming earnings report. The company is scheduled to release its earnings on October 31, 2024. The company's upcoming EPS is projected at $0.91, signifying a 4.6% increase compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $1.56 billion, showing a 2.74% escalation compared to the year-ago quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $4.29 per share and a revenue of $6.35 billion, indicating changes of +3.62% and +1.32%, respectively, from the former year.
Investors might also notice recent changes to analyst estimates for Organon. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.48% lower. Organon currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Organon is currently trading at a Forward P/E ratio of 4.11. This signifies a discount in comparison to the average Forward P/E of 20.32 for its industry.
Meanwhile, OGN's PEG ratio is currently 0.75. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical Services industry currently had an average PEG ratio of 1.85 as of yesterday's close.
The Medical Services industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 173, finds itself in the bottom 32% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.